Victoria Moreno

Madrid, MD 28046, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD.

Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD.

Journal: Biomedicines

Published: April 12, 2024

Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".

Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".

Journal: EBioMedicine

Published: February 22, 2023

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

Journal: Open forum infectious diseases

Published: September 30, 2022

Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV.

Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: July 30, 2022

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.

Journal: AIDS (London, England)

Published: July 18, 2022

Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.

Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.

Journal: Frontiers in pharmacology

Published: May 10, 2022

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.

Journal: Open forum infectious diseases

Published: January 11, 2022

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).

Journal: The Journal of antimicrobial chemotherapy

Published: April 01, 2021

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: July 15, 2020

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: July 15, 2020

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.

Journal: The Journal of antimicrobial chemotherapy

Published: July 15, 2020

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).

Journal: EBioMedicine

Published: February 21, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026